Company Profile

PFE insider trades (13 months) →

Today's multi-factor rank: 312 of 466 · see the ranking

Quant500 Scores

Momentum

5.3/10

Value

5.1/10

Growth

3.5/10

Quality

5.0/10

Multifactor

4.7/10

Market and Valuation

Price & Market

Prev Close Price:$27.64

Open:$27.64

Day's Low:$27.34

Day's High:$27.66

Bid / Ask:-

Market Cap:157.65B

Enterprise Value:209.73B

52-Week Range

52-Week Low:$23.58

52-Week High:$29.21

Current position in 52-week range

52w Low-52w High

50-Day Avg:$26.62

200-Day Avg:$26.27

Volume

Volume Today:75,434,065

Avg Volume (3m):40,819,058

Avg Volume (10d):33,863,960

52-Week Change:+15.06%

vs S&P 500, 52 weeks:-

Beta:0.30

Valuation Multiples

PER Trailing:36.39

PER Forward:9.55

PEG Ratio:12.56

Price / Book:1.85

Price / Sales (TTM):2.48

EV / Revenue:3.29

EV / EBITDA:8.26

Dividends

Current yield:6.22%

Annual Dividend Rate:$1.72

Dividend Trailing:$1.72

Yield Trailing:6.22%

5-Year Avg Yield:5.20%

Payout Ratio:226.32%

Last Ex-Dividend Date:-

Valuation Context

P/E vs sector (indicative)

Most Recent Quarter:-

Fiscal Year (Next):-

Date Filter (Month):

Loading historical OHLCV database...

Financial Statements TTM (Trailing 12 Months)

Income Statement

Total Revenue (TTM):63.70B

Gross Profit:47.59B

EBITDA:25.38B

Net Income (TTM):4.34B

Rev Growth (YoY):+2.60%

Earnings Growth (YoY):-

Quarterly earnings growth (YoY):-

Margins

Gross Margin:-

EBITDA Margin:-

Operating Margin:-

Net Margin:-

Per Share

EPS Trailing (TTM):-

EPS Forward (Est.):$2.90

Revenue Per Share:$11.19

Cash Per Share:-

Book Value:$14.95

Last Dividend:-

Ex-Dividend Date:-

Last Split:-

Balance Sheet & Liquidity

Total cash:11.70B

Total Debt:63.48B

Net Debt (Debt - Cash):51.78B

Debt / Equity:74.25%

Current Ratio:1.27

Quick Ratio:0.85

Cash Flows

Operating Cash Flow:13.40B

Free Cash Flow (FCF):12.49B

FCF Yield (FCF / Market Cap):-

Enterprise Value:209.73B

EV / Revenue:3.29

EV / EBITDA:8.26

Profitability

ROE (Return on Equity):5.01%

ROA (Return on Assets):5.78%

PER Trailing:36.39

PER Forward:9.55

Price / Book:1.85

PEG Ratio:12.56

52-Week Change:+15.06%

S&P 500 change, 52 weeks:+14.80%

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

EPS Trailing (TTM):$0.76

EPS Forward (Est.):$2.90

PER Forward:-

PEG Ratio:12.56

Growth and Margins

Earnings Growth YoY:-

Quarterly Earnings Growth YoY:-

Rev Growth YoY:-

Net Margin:-

Gross Margin:-

EBITDA Margin:-

Per Share

Revenue Per Share:$11.19

Cash Per Share:-

Book Value:$14.95

Cash Flows (TTM)

Free Cash Flow:12.49B

Operating Cash Flow:13.40B

EBITDA:25.38B

Total Revenue (TTM):63.70B

Net Income (TTM):4.34B

Fiscal Year (Last):-

EPS Surprise History - Last 4 Quarters

Actual vs. Analyst Estimates · Green = beat expectations · Red = missed

Quarter	Period	Actual EPS	Estimated EPS	Difference	Surprise %	Currency

Ownership Structure

Ownership Distribution

% Insiders:-

% Institutional:-

% Inst. (of Float):-

No. of Institutions:-

Visual distribution

InsidersInstitutionalFree Float

Shares & Short Interest

Shares Outstanding:5,699,673,589

Float (free shares):5,692,036,026

Short interest (shares):151,537,890

Short % of float:-

Short Ratio (days to cover):3.91

Short interest, prior month:-

Short Interest Date:-

Governance Score (1=Best, 10=Worst)

Overall risk:-

Audit Risk:-

Board risk:-

Compensation Risk:-

Shareholder rights risk:-

Top Institutional Holders

Position Change: ▲ Increased · ▼ Reduced · = Unchanged

Organization	Report Date	% Shares	No. Shares	Value (USD)	Change %

Top Mutual Funds

Position Change: ▲ Increased ▼ Decreased = Unchanged

Fund	Report Date	% Shares	No. Shares	Value (USD)	Change %

Recent Insider Trades

Executive / Insider	Title	Date	Action	Shares

Options Chain

Expiration Date:

CALLS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

PUTS

Strike	Last	Bid	Ask	Vol.	O.I.	IV

Pfizer Inc. (PFE) SEC filings: 10-K, 10-Q and 8-K

Direct links to financial reports filed with the SEC.

Type	Date	Official link
N-PX	2026-08-31	View filing ↗
8-K	2026-08-04	View filing ↗
8-K	2026-06-18	View filing ↗
11-K	2026-06-16	View filing ↗
S-8	2026-05-05	View filing ↗
8-K	2026-04-27	View filing ↗
DEFA14A	2026-03-12	View filing ↗
10-K	2026-02-26	View filing ↗
8-K	2026-02-03	View filing ↗
8-K	2025-12-16	View filing ↗

Company and Executive Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

General Information

Headquarters:United States

City:New York

Employees:75,000

Sector:Healthcare

Industry:Drug Manufacturers - General

Website:-

Key Executives

Name	Title	Age	Total pay
Dr. Albert Bourla D.V.M., Ph.D.	Chairman of the Board & CEO	63	9.14M
Dr. Chris Boshoff FMedSci, M.D., Ph.D.	Chief Scientific Officer and President of Research & Development	61	5.20M
Mr. Douglas M. Lankler	Executive VP & Chief Legal Officer	59	4.62M
Mr. Aamir Malik	Executive VP & Chief U.S. Commercial Officer	49	4.90M
Ms. Cecile Guegan	Interim CFO & Executive VP	54	-
Ms. Jennifer B. Damico	Senior VP, Controller & Principal Accounting Officer	56	-
Mr. Dennis P. Hancock	Executive VP & Chief Information Officer	-	-
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	-	-

You have seen the engine room

Few finance sites let you get this far, and none we know of also shows you where its knowledge ends. If this way of working convinces you, the thing almost nobody catches in time can reach you by email: the big insider buys — executives and major shareholders putting in their own money — the same day they report them to the SEC, with the Form 4 linked. It takes three steps and none of them costs anything: create the account, confirm the email we send you, then switch the alert on in your profile (the icon at the top right). It starts off and it goes off again with the same click. Along the way all three are saved: your simulator portfolios, your personal portfolio and your Academy progress, synced across devices.

No card. No spam.

Pfizer Inc. (PFE): Quantitative Analysis

Name: Factor scores for Pfizer Inc. (PFE)
Creator: Quant500
License: https://quant500.com/legal

Pfizer Inc. (PFE) — Healthcare — Drug Manufacturers - General. PFE is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.

So far in 2026, PFE has returned +16.3% against +12.2% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Sep 18, 2026.

PFE ranks 312 of 466 on today's multifactor score, and 42 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.18, ranked 182 of 497); its weakest is growth (Z -0.93, ranked 475 of 494). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.

Factor scores

The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.

Factor	Z-Score	Rank
Multifactor	-0.169	312 of 466 ↑21
Momentum	0.175	182 of 497 ↑30
Value	0.059	189 of 494 ↓2
Quality	0.015	204 of 473 =
Growth	-0.925	475 of 494 =

Market data

Metric	Value
Price	$27.66
Market Cap	157.65B
P/E	36.39
Revenue (last 12 months)	63.70B
Price / book	1.85
Book value per share	$14.95
52-week range	$23.58 – $29.21
Dividend yield	6.22%
Beta	0.30
Average volume	40,819,058
Shares outstanding	5.70B
Short interest (% of float)	2.66% (as of Aug 31, 2026)

When does PFE report earnings? 12 of its last 12, before the open →

What are PFE insiders doing? 26 transactions filed with the SEC, of them 3 buys and 2 sells, the last one on Aug 12, 2026 →

Data as of Sep 18, 2026. Source: point-in-time SEC fundamentals and closing prices. Method and formulas are on the home page.

Company Profile

Market and Valuation

Price & Market

52-Week Range

Volume

Valuation Multiples

Dividends

Valuation Context

Financial Statements TTM (Trailing 12 Months)

Income Statement

Margins

Per Share

Balance Sheet & Liquidity

Cash Flows

Profitability

Historical Evolution (Last 4 Years)

Income Statement

Balance Sheet

Cash Flow

EPS and Earnings Per Share

Key EPS Metrics

Growth and Margins

Per Share

Cash Flows (TTM)

EPS Surprise History - Last 4 Quarters

Ownership Structure

Ownership Distribution

Shares & Short Interest

Governance Score (1=Best, 10=Worst)

Top Institutional Holders

Top Mutual Funds

Recent Insider Trades

Options Chain

CALLS

PUTS

Sentiment Metrics

Expected move

Pfizer Inc. (PFE) SEC filings: 10-K, 10-Q and 8-K

Company and Executive Profile

General Information

Key Executives

You have seen the engine room

Pfizer Inc. (PFE): Quantitative Analysis

Factor scores

Market data